Endovascular transplantation of mRNA-enhanced mesenchymal stromal cells results in superior therapeutic protein expression in swine heart.

cardiology cell transplantation endovascular intervention endovascular intramyocardial transplantation heart failure mRNA drug products mesenchymal stromal cells modRNA trans-vessel wall device vascular endothelial growth factor

Journal

Molecular therapy. Methods & clinical development
ISSN: 2329-0501
Titre abrégé: Mol Ther Methods Clin Dev
Pays: United States
ID NLM: 101624857

Informations de publication

Date de publication:
13 Jun 2024
Historique:
received: 21 06 2023
accepted: 23 02 2024
medline: 22 3 2024
pubmed: 22 3 2024
entrez: 22 3 2024
Statut: epublish

Résumé

Heart failure has a poor prognosis and no curative treatment exists. Clinical trials are investigating gene- and cell-based therapies to improve cardiac function. The safe and efficient delivery of these therapies to solid organs is challenging. Herein, we demonstrate the feasibility of using an endovascular intramyocardial delivery approach to safely administer mRNA drug products and perform cell transplantation procedures in swine. Using a

Identifiants

DOI: 10.1016/j.omtm.2024.101225 PMID: 38516693 PMC: PMC10950887
pubmed: 38516693
doi: 10.1016/j.omtm.2024.101225
pii: S2329-0501(24)00041-X
pmc: PMC10950887
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101225

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

R.G., J.L., N.W., and S.H. are shareholders of SmartCella Holding AB that has the IP rights to the Extroducer (trans-vessel wall device).

Auteurs

Jonathan Al-Saadi (J)

Department of Clinical Neuroscience, Karolinska Institute, Tomtebodavägen 18A, 171 65 Stockholm, Sweden.
Department of Neuroradiology, Karolinska University Hospital, 171 64 Stockholm, Sweden.
MedTechLabs, Stockholm, Sweden.

Mathias Waldén (M)

Department of Clinical Neuroscience, Karolinska Institute, Tomtebodavägen 18A, 171 65 Stockholm, Sweden.

Mikael Sandell (M)

Department of Clinical Neuroscience, Karolinska Institute, Tomtebodavägen 18A, 171 65 Stockholm, Sweden.
MedTechLabs, Stockholm, Sweden.
Division of Micro and Nanosystems, KTH Royal Institute of Technology, Malvinas väg 10, 114 28 Stockholm, Sweden.

Jesper Sohlmér (J)

Department of Cell and Molecular Biology, Karolinska Institute, Solnavägen 9, 171 65 Stockholm, Sweden.

Rikard Grankvist (R)

Department of Clinical Neuroscience, Karolinska Institute, Tomtebodavägen 18A, 171 65 Stockholm, Sweden.

Ida Friberger (I)

Department of Clinical Neuroscience, Karolinska Institute, Tomtebodavägen 18A, 171 65 Stockholm, Sweden.

Agneta Andersson (A)

Department of Medicine, Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden.

Mattias Carlsten (M)

Department of Medicine, Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden.
Center for Cell Therapy and Allogeneic Stem Cell Transplantation, Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden.

Kenneth Chien (K)

Department of Cell and Molecular Biology, Karolinska Institute, Solnavägen 9, 171 65 Stockholm, Sweden.

Johan Lundberg (J)

Department of Clinical Neuroscience, Karolinska Institute, Tomtebodavägen 18A, 171 65 Stockholm, Sweden.
Department of Neuroradiology, Karolinska University Hospital, 171 64 Stockholm, Sweden.
MedTechLabs, Stockholm, Sweden.

Nevin Witman (N)

Department of Clinical Neuroscience, Karolinska Institute, Tomtebodavägen 18A, 171 65 Stockholm, Sweden.

Staffan Holmin (S)

Department of Clinical Neuroscience, Karolinska Institute, Tomtebodavägen 18A, 171 65 Stockholm, Sweden.
Department of Neuroradiology, Karolinska University Hospital, 171 64 Stockholm, Sweden.
MedTechLabs, Stockholm, Sweden.

Classifications MeSH